What are the contraindications for prescribing pirenzepine?

A contraindication for the use of muscarinic antagonists, including pirenzepine, is glaucoma. At the same time, the drug features a high safety profile because at average therapeutic doses it does not block $M_2$ and $M_3$ receptors. Due to its selective action, there are practically no systemic side effects characteristic of non-selective atropine-like agents. In particular, pirenzepine does not affect pupil size or accommodation, does not alter heart rate or atrioventricular conduction, and does not decrease intestinal smooth muscle tone and peristalsis.

Why is pirenzepine safer than atropine in the treatment of peptic ulcer disease?

Pirenzepine selectively blocks $M_1$ receptors without affecting $M_2$ and $M_3$ receptors. This avoids the systemic side effects of atropine: tachycardia, mydriasis, and cycloplegia.

Does pirenzepine cross the blood-brain barrier?

No, the drug poorly crosses histohematic barriers, including the blood-brain barrier, and therefore has no effect on the central nervous system.

How does pirenzepine affect hydrochloric acid production?

It blocks $M_1$ receptors on ECL cells, reducing the release of histamine, which is a stimulant for parietal cells. As a result, hydrochloric acid production is secondarily decreased.

Home › Pharmacology › Pirenzepine

Pirenzepine

Pirenzepinum

For medical students2 min readUpdated 2026-10-10

Pirenzepine is a selective $M_1$ muscarinic receptor antagonist belonging to drugs that regulate the peripheral nervous system. The drug effectively reduces hydrochloric acid secretion while maintaining a higher safety profile compared to non-selective anticholinergics.

Mechanism of ActionSelective blockade of $M_1$ muscarinic receptors in intramural ganglia and ECL cells.

FormulationsTablets 25 mg and 50 mg; 0.5% ampoules 2 ml.

Clinical ApplicationAntisecretory agent for gastric and duodenal ulcer disease.

PharmacokineticsPoorly crosses the blood-brain barrier; has no central nervous system effects.

Mechanism of Action

Pirenzepine selectively blocks $M_1$ muscarinic receptors located in the intramural ganglia, G-cells, and enterochromaffin-like (ECL) cells of the stomach. At therapeutic doses, the drug does not affect $M_2$ and $M_3$ receptors. The primary effect is achieved by inhibiting the release of histamine and gastrin, which secondarily decreases hydrochloric acid production by parietal cells.

Pharmacological Effects

Due to its selectivity, pirenzepine lacks the systemic effects characteristic of atropine. It does not affect heart rate, atrioventricular conduction, pupil size, accommodation, or intestinal peristalsis. The drug practically does not cross the blood-brain barrier, which excludes any effects on the central nervous system.

Indications

The primary indication is gastric and duodenal ulcer disease. The drug is used as an antisecretory agent to reduce the volume and acidity of gastric juice while maintaining a high safety profile for the patient.

Side Effects

Despite high selectivity, local manifestations are possible: dry mouth (due to a minor reduction in salivary gland secretion). Mild near-vision disturbances, diarrhea, bulimia, or allergic reactions are less common.

Administration

The drug is taken orally before meals at 50 mg 2–3 times a day. For parenteral administration (IV or IM), the dosage is 5–10 mg 2–3 times a day. The contents of the ampoule are diluted in 15–20 ml of 0.9% NaCl solution and administered intravenously slowly over 3–4 minutes.

Mnemonic

Pirenzepine — "Gastrozepin": blocks $M_1$ so the stomach "sleeps" (reduces acid), but doesn't "touch" the heart and eyes.

Frequently asked questions

What are the contraindications for prescribing pirenzepine?: A contraindication for the use of muscarinic antagonists, including pirenzepine, is glaucoma. At the same time, the drug features a high safety profile because at average therapeutic doses it does not block $M_2$ and $M_3$ receptors. Due to its selective action, there are practically no systemic side effects characteristic of non-selective atropine-like agents. In particular, pirenzepine does not affect pupil size or accommodation, does not alter heart rate or atrioventricular conduction, and does not decrease intestinal smooth muscle tone and peristalsis.
Why is pirenzepine safer than atropine in the treatment of peptic ulcer disease?: Pirenzepine selectively blocks $M_1$ receptors without affecting $M_2$ and $M_3$ receptors. This avoids the systemic side effects of atropine: tachycardia, mydriasis, and cycloplegia.
Does pirenzepine cross the blood-brain barrier?: No, the drug poorly crosses histohematic barriers, including the blood-brain barrier, and therefore has no effect on the central nervous system.
How does pirenzepine affect hydrochloric acid production?: It blocks $M_1$ receptors on ECL cells, reducing the release of histamine, which is a stimulant for parietal cells. As a result, hydrochloric acid production is secondarily decreased.

Go deeper

Comparative characteristics of selective $M_1$ anticholinergics and $H_2$ histamine receptor antagonists.
The role of ECL cells in the regulation of gastric secretion.
Principles of differential diagnostics for antisecretory agents.
Pharmacodynamics of non-selective muscarinic antagonists (atropine-like drugs) and reasons for their limitations in peptic ulcer therapy.
Mechanisms of side effects during muscarinic receptor stimulation.